What is RMDA's market capitalization?

Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda has a market capitalization of about EGP 10.2B.

Does RMDA pay dividends?

Yes — Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda paid EGP 0.03 per share for fiscal 2025, a dividend yield of 0.6% at the last price.

What is RMDA's P/E ratio?

Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda trades at a trailing price-to-earnings ratio of 29.63.

Where can I track RMDA?

This Starta Markets page shows Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda's EGX quote (delayed 15 minutes), key statistics, financial statements, dividends, technicals and news, in Arabic and English.

Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda (RMDA) Share Price — EGX

EGP 5.02-1.18%Indicator average: −0.20 (−1 to +1)

Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda (RMDA) trades on the Egyptian Exchange (EGX) in the Health Care & Pharmaceuticals sector. Last updated 28 Oct 2026, 14:30 (Cairo time).

What is Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda’s share price today? RMDA last traded at EGP 5.02 (-1.18% on the day), for a market value of EGP 10.20 billion, a P/E of 29.63 and a dividend yield of 0.60%. Its 52-week range is EGP 3.06 to 7.39.

RMDA price performance

1W: -2.7%
1M: -5.3%
3M: -3.8%
6M: +9.6%
YTD: +50.8%
1Y: +51.4%
5Y: +266.6%

Price change from EGX closing prices, adjusted for recorded splits and bonus issues; cash dividends are not included. A period that spans an unexplained price jump is not shown. Past performance does not indicate future results.

About Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda

Tenth of Ramadan Company for Pharmaceuticals Industries & Diagnostic Reagents S.A.E. engages in the manufacture and marketing of pharmaceutical products for human and veterinary use. It operates through Production and Selling of Pharmaceutical Products; and Manufacturing for Others segments. The firm product categories include anti-infective, anti-diabetic, respiratory, ophthalmology, gastro-intestinal tract, cardio-vascular, central nervous system, vitamins, and analgesics. The company was founded on January 15, 1986 and is headquartered in 6th of October City, Egypt.

Industry:: Pharmaceuticals: Major
CEO:: Amr Morsy
ISIN:: EGS381B1C015
Website:: www.ramedapharma.com

RMDA key statistics

Last price: EGP 5.02
Previous close: EGP 5.08
Day change: -1.18%
52-week range: EGP 3.06 – 7.39
Volume: 3,519,344
Shares outstanding: 2.03B
Free float: 67.68%
Market cap: EGP 10.2B
P/E (trailing): 29.63
P/B: 3.5
Dividend yield (FY 2025): 0.6%
EPS (TTM): EGP 0.17
Revenue (TTM): EGP 4.39B
Net income (TTM): EGP 330.86M
ROE: 13.75%
Book value / share: EGP 1.15
Beta (1Y): 0.64
50-day MA: EGP 5.69
200-day MA: EGP 4.84
RSI (14): 42.66

Data as of 28 Oct 2026, 14:30 (Cairo time). EGX market data; financial statements from company disclosures. Prices are delayed 15 minutes during EGX trading hours (Sun–Thu).

Compare with other Health Care & Pharmaceuticals stocks

Latest Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda news

LVP Pharma nearly doubles shareholding in Rameda for EGP 1.1bn19 Mar 2026
Rameda’s stock regains momentum after correction2 Mar 2026
LVP PHARMA ups stake in Rameda for EGP 215m22 Feb 2026

Key terms behind the RMDA figures

Market Capitalization: Market capitalization is the total market value of a company’s outstanding shares, calculated as the share price multiplied by the number of issued shares. It is the standard measure used to rank the size of listed companies and to weight them in indices such as the EGX 30. Market cap changes continuously as the share price moves.
Price-to-Earnings (P/E) Ratio: The price-to-earnings ratio divides a company’s share price by its earnings per share, showing how many pounds investors pay for each pound of annual profit. It is one of the most widely used valuation multiples for comparing listed companies within the same sector. A trailing P/E uses reported earnings, while a forward P/E uses forecast earnings.
Price-to-Book (P/B) Ratio: The price-to-book ratio compares a company’s share price with its book value per share, which is shareholders’ equity divided by the number of shares. A ratio of 1 means the stock trades at exactly its accounting net worth. The multiple is used widely for valuing banks and other asset-heavy businesses on the EGX.
Dividend Yield: Dividend yield is the annual cash dividend per share expressed as a percentage of the current share price. It measures the income a shareholder receives from distributions relative to the market price of the stock. Because the calculation uses the market price, the yield rises when the price falls and falls when the price rises, assuming the dividend is unchanged.

Frequently asked questions

What is Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda (RMDA) share price today?: Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda last traded at EGP 5.02 on the Egyptian Exchange (as of 28 Oct 2026, 14:30, Cairo time). Prices update every 15 minutes during EGX trading hours.
What is RMDA's market capitalization?: Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda has a market capitalization of about EGP 10.2B.
Does RMDA pay dividends?: Yes — Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda paid EGP 0.03 per share for fiscal 2025, a dividend yield of 0.6% at the last price.
What is RMDA's P/E ratio?: Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda trades at a trailing price-to-earnings ratio of 29.63.
What sector is Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda in?: Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda is listed on the Egyptian Exchange (EGX) in the Health Care & Pharmaceuticals sector.
Where can I track RMDA?: This Starta Markets page shows Tenth of Ramadan Pharmaceutical Industries & Diagnostic-Rameda's EGX quote (delayed 15 minutes), key statistics, financial statements, dividends, technicals and news, in Arabic and English.